Enliven Therapeutics, Inc. 8-K

What Happened
Enliven Therapeutics, Inc. announced its financial results for the quarter and year ended December 31, 2025 by issuing a press release on March 3, 2026. The company furnished the press release as Exhibit 99.1 to an 8-K under Item 2.02 (Results of Operations and Financial Condition).

Key Details

• Press release issued March 3, 2026 reporting quarterly and full-year 2025 results (quarter and year ended December 31, 2025).
• Full text of the press release is attached to the 8-K as Exhibit 99.1.
• The exhibit and related information were furnished (Item 9.01 note) and are not deemed “filed” under Section 18 of the Exchange Act.
• The furnished materials are not automatically incorporated by reference into other SEC filings unless expressly stated.

Why It Matters
This 8-K notifies investors that Enliven has released its latest earnings and revenue-related results; investors should review Exhibit 99.1 for the specific figures (revenue, profit/loss, cash position, guidance, if provided). The legal note that the release is “furnished” (not “filed”) affects how that information is treated for liability and incorporation into future SEC filings.